• Overview
  • Eligibility
  • More info
  • Locations

Phase II Trial of Dolastatin-10 in Patients With Previously Untreated Recurrent/Metastatic Sarcoma (NCT00003778)

Phase II trial to study the effectiveness of dolastatin 10 in treating patients who have recurrent or metastatic soft tissue sarcoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
  • Drug: dolastatin 10
    Ages eligible for Study
    18 Years and older
    Genders eligible for Study
    Accepts Healthy Volunteers

    I. Determine the response rate in patients with recurrent or metastatic soft tissue sarcomas treated with dolastatin 10.

    II. Determine the toxicity of this regimen in this patient population.

    OUTLINE: This is an open label, multicenter study. Patients are stratified according to center, prior therapy, histologic subtype, stage of disease at diagnosis, and current status of disease (recurrent vs metastatic).

    Patients receive dolastatin 10 IV over 10 minutes. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

    Patients are followed at 1 month.

    4 locations

    United States (4)
    • University of Colorado Cancer Center
      Not specified
      Denver, Colorado, United States, 80262
    • Mayo Clinic Cancer Center
      Not specified
      Rochester, Minnesota, United States, 55905
    • Arthur G. James Cancer Hospital - Ohio State University
      Not specified
      Columbus, Ohio, United States, 43210
    • Fox Chase Cancer Center
      Not specified
      Philadelphia, Pennsylvania, United States, 19111
    31 March, 1999
    06 February, 2013
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!